Elevai Labs Inc. (ELAB)
NASDAQ: ELAB · Real-Time Price · USD
0.0203
-0.0011 (-5.14%)
Nov 21, 2024, 2:34 PM EST - Market open
Elevai Labs Revenue
Elevai Labs had revenue of $527.48K in the quarter ending September 30, 2024, a decrease of -4.90%. This brings the company's revenue in the last twelve months to $2.45M, up 112.17% year-over-year. In the year 2023, Elevai Labs had annual revenue of $1.71M with 123.50% growth.
Revenue (ttm)
$2.45M
Revenue Growth
+112.17%
P/S Ratio
0.15
Revenue / Employee
$135,898
Employees
18
Market Cap
1.00M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.71M | 946.32K | 123.50% |
Dec 31, 2022 | 766.28K | 765.45K | 92,557.44% |
Dec 31, 2021 | 827.00 | - | - |
Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionELAB News
- 7 days ago - CORRECTION - Elevai Labs Inc. - GlobeNewsWire
- 7 days ago - Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update - GlobeNewsWire
- 16 days ago - Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange - GlobeNewsWire
- 4 weeks ago - Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity - GlobeNewsWire
- 4 weeks ago - Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity - GlobeNewsWire
- 6 weeks ago - Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock - GlobeNewsWire
- 6 weeks ago - REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations - GlobeNewsWire
- 7 weeks ago - Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations - GlobeNewsWire